Current price is more than the intrinsic value

Intrinsic Value

Stock has been generating better return on equity than bank FD

Returns vs FD rates

Stock doesn't offer attractive dividend returns

Dividend Returns

Good time to consider, as stock is not in overbought zone

Entry Point

Stock not in ASM/GSM lists and not a lot of promoter holding is pledged

No Red Flags

#CNBCAwaazLive #AajKaTajaKhabar #LaurusLabs #LaurusLabsShare #BusinessNewsLive #StockMarketLive #ShareMarketLive

Laurus Labs में दिख रही है अच्छी तेजी। इस Stock में जानें निवेश को लेकर क्या है Expert की राय. साथ ही जानें Expert की है खरीदारी की राय, पाएं आगे की रणनीति. देखें वीडियो. 


Share Market से जुड़ी हर छोटी या बड़ी खबर, चाहे हो Nifty में आए नए हाई या फिर, हो आपके के लिए स्टॉक्स पर राय, बिजनेस न्यूज हो या पॉलिटिकल न्यूज, कोरोनावायरस की न्यूज हो या फिर इलेक्शन, देखें CNBC Awaaz और रहे हर खबर से updated.


CNBC Awaaz is India’s number one business channel and an undisputed leader in business news and information for the last ten years. Our channel aims to educate, inform and inspire consumers to go beyond limitations, with practical tips on personal finance, investing, technology, consumer goods and capital markets. Policymakers and business owners alike have grown to trust CNBC Awaaz as the most reliable source with its eye on India’s business climate. Our programming gives consumers a platform to make decisions with confidence.

Subscribe to the CNBC Awaaz YouTube channel here: https://tinyurl.com/y5rsvesk

Follow CNBC Awaaz on Twitter: https://twitter.com/CNBC_Awaaz
Like us on our CNBC Awaaz Facebook page: https://www.facebook.com/cnbcawaaz

Laurus Labs में दिख रही है अच्छी तेजी, पाएं आगे की रणनीति | Markets Today | CNBC Awaaz

#CNBCAwaazLive #BusinessNewsLive #StockMarket #ShareMarketToday 

Piramal Enterprises और Laurus Labs पर Prakash Gaba ने खरीदारी की सलाह दी है। इन दोनों ही Stocks पर तेजी जारी है और यहां इस समय निवेश करना निवेशकों के लिए कितना बेहतर रहेगा इसी पर करेगी खास चर्चा, देखें वीडियो

Share Market से जुड़ी हर छोटी या बड़ी खबर, चाहे हो Nifty में आए नए हाई या फिर, हो आपके के लिए स्टॉक्स पर राय, बिजनेस न्यूज हो या पॉलिटिकल न्यूज, कोरोनावायरस की न्यूज हो या फिर इलेक्शन, देखें CNBC Awaaz और रहे हर खबर से updated.


CNBC Awaaz is India’s number one business channel and an undisputed leader in business news and information for the last ten years. Our channel aims to educate, inform and inspire consumers to go beyond limitations, with practical tips on personal finance, investing, technology, consumer goods and capital markets. Policymakers and business owners alike have grown to trust CNBC Awaaz as the most reliable source with its eye on India’s business climate. Our programming gives consumers a platform to make decisions with confidence.

Subscribe to the CNBC Awaaz YouTube channel here: https://tinyurl.com/y5rsvesk

Follow CNBC Awaaz on Twitter: https://twitter.com/CNBC_Awaaz
Like us on our CNBC Awaaz Facebook page: https://www.facebook.com/cnbcawaaz

Piramal Enterprises और Laurus Labs पर Prakash Gaba ने दी Buying की सलाह, जानें Target

Laurus Labs Ltd is quoting at Rs 523.45, up 4.25% on the day as on 12:54 IST on the NSE. The stock is up 79.05% in last one year as compared to a 34.53% jump in NIFTY and a 14.62% jump in the Nifty Pharma index.

Laurus Labs Ltd up for third consecutive session

Here’s what Gaurav Sharma of Globe Capital Markets, recommends investors should do with these stocks when the market resumes trading today.

Trade Spotlight | What Should You Do With ONGC, Laurus Labs, Adani Ports, Zee Stocks?

Motilal Oswal is bullish on Laurus Labs recommended buy rating on the stock with a target price of Rs 690 in its research report dated November 21, 2021.

Buy Laurus Labs; Target Of Rs 690: Motilal Oswal

1) Bharti Airtel
Announces tariff hike for pre paid plans. Prepaid customers account for 94.7% total subscribers. This is the second hike, last was announced in July 2021. Pricing of entry level pack is up 25%; Rest is  average 20% higher. Maintains ARPU needs to be at Rs 200 and ultimately at Rs 300. ARPU at end of Q2 stood at Rs 153

2) RIL RIL and Saudi Aramco re-evaluate proposed investment in Reliance’s O2C business. Application with NCLT for segregating the O2C business from RIL withdrawn.
3) ONGC The company signs initial pact with Saudi Aramco to explore a strategic alliance on a broad range of energy products for the domestic market. Companies will look into long-term supply contracts for the sale and purchase of crude, refined petroleum and petrochemical products.

4) HALCompany gets Rs 357 cr contract from federal government for procurement of two Fixed Base Full Mission Simulators for Jaguar Aircraft for the Indian Air Force.

5) IRCTCIRCTC to Resume Serving Cooked Meals to Passengers on Trains. The Co withdraws its decision to terminate all existing contracts of mobile catering. 
6) Cadila Healthcare Zydus Cadila receives final approval from USFDA for Decitabine Injection 
7) Laurus Labs Agreed to acquire a 26.6% stake in ImmunoACT for a consideration of `46cr
Subscribe To ET Now For Latest Updates On Stocks, Business, Trading | ► https://goo.gl/SEjvK3

Subscribe Now To Our Network Channels :-
Times Now  : http://goo.gl/U9ibPb
The NewsHour Debate : http://goo.gl/LfNgFF

To Stay Updated Download the Times Now App :-
Android Google Play :  https://goo.gl/zJhWjC
Apple App Store :  https://goo.gl/d7QBQZ

Social Media Links :-
Twitter - http://goo.gl/hA0vDt
Facebook - http://goo.gl/5Lr4mC
G+ - http://goo.gl/hYxrmj
Website - www.etnownews.com

Stocks to watch today: Bharti Airtel, HAL Company, Laurus Labs and more

Zydus Cadila said it has received approval from the US health regulator to market Decitabine injection, used to treat certain types of cancers, in the American market.

Stocks in the news: Paytm, Latent View, Reliance Ind, Sun Pharma, IRB Infra and Laurus Labs

Additionally, Laurus Labs’ senior management will also invest in ImmunoACT for a 5.64 percent stake for approximately Rs 9.75 crore at the same price and terms, the company said in a BSE filing

Laurus Labs Acquires 26.62% Stake In ImmunoACT For Rs 46 Crore

Laurus Labs has signed an investment agreement with Immunoadoptive Cell Therapy Pvt. Ltd. (ImmunoACT) to acquire 26.62% stake in the advanced cell and gene therapy firm for a cash consideration of abo

Laurus Labs to buy 26% stake in cell therapy firm ImmunoACT for ₹46 cr.

Laurus labs investment in ImmunoACT is part of the larger strategy to strengthen biologics business of the firm

Laurus Labs signs pact to acquire 26.62 % stake in ImmunoACT

As per the agreement, Laurus will acquire 26.62% stake (fully diluted basis) for a cash consideration of approximately Rs 46 crores, subject to the fulfilment of certain conditions.

Laurus Labs acquires stake in IIT-Bombay incubated CAR-T cell therapy company

Laurus Labs Private Ltd is a research and development pharmaceutical company which manufactures active pharmaceutical ingredients (APIs) for anti-retroviral (ARV) and Hepatitis C. It also manufactures APIs in oncology and other therapeutic areas.

Laurus Labs Ltd

Laurus Labs Ltd

Intrinsic Value
Intrinsic value is the calculated value of the company and may differ from current stock price. If intrinsic value > current price, price increase is expected in the future to reduce the gap and vice-versa

Returns vs FD rates
Fixed Deposit rate is a virtually risk-free rate where the investor assumes almost no risk on their investment. If stock's return on equity is lower than this rate, investors are better off investing the amount in a FD

Dividend Returns
A dividend is the distribution of reward from a portion of company's earnings and is paid to its shareholders. Good dividend returns indicate good health and outlook for the company

Entry Point
High demand for a stock increases its price. If the price is pushed up to a level which is not justified, then it's considered to be in the overbought zone, which is not a good time to buy the stock

News & Opinions

News Video

Laurus Labs में दिख रही है अच्छी तेजी, पाएं आगे की रणनीति | Markets Today | CNBC Awaaz

News Video

Piramal Enterprises और Laurus Labs पर Prakash Gaba ने दी Buying की सलाह, जानें Target

Laurus Labs Ltd up for third consecutive session

Trade Spotlight | What Should You Do With ONGC, Laurus Labs, Adani Ports, Zee Stocks?

Buy Laurus Labs; Target Of Rs 690: Motilal Oswal

News Video

Stocks to watch today: Bharti Airtel, HAL Company, Laurus Labs and more

Stocks in the news: Paytm, Latent View, Reliance Ind, Sun Pharma, IRB Infra and Laurus Labs

Laurus Labs Acquires 26.62% Stake In ImmunoACT For Rs 46 Crore

Laurus Labs to buy 26% stake in cell therapy firm ImmunoACT for ₹46 cr.

Laurus Labs signs pact to acquire 26.62 % stake in ImmunoACT

Laurus Labs Ltd

Intrinsic ValueIntrinsic value is the calculated value of the company and may differ from current stock price. If intrinsic value > current price, price increase is expected in the future to reduce the gap and vice-versa

Returns vs FD ratesFixed Deposit rate is a virtually risk-free rate where the investor assumes almost no risk on their investment. If stock's return on equity is lower than this rate, investors are better off investing the amount in a FD

Dividend ReturnsA dividend is the distribution of reward from a portion of company's earnings and is paid to its shareholders. Good dividend returns indicate good health and outlook for the company

Entry PointHigh demand for a stock increases its price. If the price is pushed up to a level which is not justified, then it's considered to be in the overbought zone, which is not a good time to buy the stock

News & Opinions

News Video

Laurus Labs में दिख रही है अच्छी तेजी, पाएं आगे की रणनीति | Markets Today | CNBC Awaaz

News Video

Piramal Enterprises और Laurus Labs पर Prakash Gaba ने दी Buying की सलाह, जानें Target

Laurus Labs Ltd up for third consecutive session

Trade Spotlight | What Should You Do With ONGC, Laurus Labs, Adani Ports, Zee Stocks?

Buy Laurus Labs; Target Of Rs 690: Motilal Oswal

News Video

Stocks to watch today: Bharti Airtel, HAL Company, Laurus Labs and more

Stocks in the news: Paytm, Latent View, Reliance Ind, Sun Pharma, IRB Infra and Laurus Labs

Laurus Labs Acquires 26.62% Stake In ImmunoACT For Rs 46 Crore

Laurus Labs to buy 26% stake in cell therapy firm ImmunoACT for ₹46 cr.

Laurus Labs signs pact to acquire 26.62 % stake in ImmunoACT

Intrinsic Value
Intrinsic value is the calculated value of the company and may differ from current stock price. If intrinsic value > current price, price increase is expected in the future to reduce the gap and vice-versa

Returns vs FD rates
Fixed Deposit rate is a virtually risk-free rate where the investor assumes almost no risk on their investment. If stock's return on equity is lower than this rate, investors are better off investing the amount in a FD

Dividend Returns
A dividend is the distribution of reward from a portion of company's earnings and is paid to its shareholders. Good dividend returns indicate good health and outlook for the company

Entry Point
High demand for a stock increases its price. If the price is pushed up to a level which is not justified, then it's considered to be in the overbought zone, which is not a good time to buy the stock